FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200490095> ?p ?o ?g. }

• W4200490095 endingPage "25" @default.
• W4200490095 startingPage "16" @default.
• W4200490095 abstract "BACKGROUND: Therapy with angiotensinconverting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) requires laboratory monitoring to avoid hyperkalemia and acute kidney failure. OBJECTIVE: To assess the frequency of recommended annual serum potassium and creatinine monitoring and determine potential factors associated with care gaps among adults dispensed an ACEI or ARB. METHODS: This mixed-methods study integrated findings from a retrospective cohort study and individual patient interviews. Adults aged 21 years and over within Kaiser Permanente Southern California with at least 180 treatment days of an ACEI and/or ARB in 2015 were included. Patients invited for qualitative interviews included those who did and did not complete the recommended laboratory tests. We assessed the proportion of patients completing both recommended laboratory tests, factors associated with not receiving laboratory monitoring, and patients' insights into barriers and facilitators of recommended monitoring. RESULTS: Of 437,544 patients who received an ACEI or ARB, 9.0% did not receive both a serum potassium and creatinine laboratory test during treatment (defined as a care gap). Lower risk of a care gap was observed for patients with increasing age (rate ratio [RR] per 10-year increase = 0.78, 95% CI = 0.77-0.79); diabetes mellitus (RR = 0.62, 95% CI = 0.60-0.64); hypertension (RR = 0.71, 95% CI = 0.71-0.74); Charlson Comorbidity Index score of at least 2 (RR = 0.62, 95% CI = 0.60-0.64); those who changed medication classes (RR = 0.53, 95% CI = 0.51-0.56); and patients with a cardiologist (RR = 0.81, 95% CI = 0.73-0.90) or nephrologist (RR = 0.60, 95% CI = 0.52-0.69) as their prescribing provider. Twenty-five patients completed the qualitative interviews. Patients often lacked knowledge about the need for laboratory monitoring, cited logistical barriers to accessing the laboratory, and deemed the reminders they received through an outpatient safety program as a facilitator to completing tests. CONCLUSIONS: Given the large patient population on ACEI and ARB medications, monitoring and support strategies such as electronic clinical surveillance could be important in addressing care gaps and potentially reducing adverse drug effects. DISCLOSURES: This project was supported by grant number R01HS024437 from the Agency for Healthcare Research and Quality. The funder had no role in the design of the study; collection, analyses, or interpretation of the data, or decision to submit this manuscript for publication. Harrison, Reynolds, Hahn, Munoz-Plaza, Yi, Fischer, Luong, Sim, Brettler, Handler, and Mittman are employees of the Southern California Permanente Medical Group. Danworth was employed by the Southern California Permanente Medical Group at the time of this study. Singh was partially supported by the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (CIN13-413). Reynolds reports grants from Novartis, Amgen Inc., and Vital Strategies, Resolve to Save Lives, unrelated to this work. Yi reports grants from Novartis unrelated to this work. Kanter has nothing to disclose." @default.
• W4200490095 created "2021-12-31" @default.
• W4200490095 creator A5010339189 @default.
• W4200490095 creator A5018333483 @default.
• W4200490095 creator A5021745572 @default.
• W4200490095 creator A5030359301 @default.
• W4200490095 creator A5035903999 @default.
• W4200490095 creator A5038649200 @default.
• W4200490095 creator A5040321180 @default.
• W4200490095 creator A5042992461 @default.
• W4200490095 creator A5051667677 @default.
• W4200490095 creator A5054838830 @default.
• W4200490095 creator A5071453510 @default.
• W4200490095 creator A5086117406 @default.
• W4200490095 creator A5087248896 @default.
• W4200490095 creator A5090025434 @default.
• W4200490095 date "2022-01-01" @default.
• W4200490095 modified "2023-10-16" @default.
• W4200490095 title "Laboratory monitoring to reduce adverse drug-related events: a mixed methods study" @default.
• W4200490095 cites W1581746603 @default.
• W4200490095 cites W1608346277 @default.
• W4200490095 cites W183021864 @default.
• W4200490095 cites W1971765404 @default.
• W4200490095 cites W1972412925 @default.
• W4200490095 cites W1987614881 @default.
• W4200490095 cites W1991106789 @default.
• W4200490095 cites W2006157113 @default.
• W4200490095 cites W2015959379 @default.
• W4200490095 cites W2052600761 @default.
• W4200490095 cites W2065923696 @default.
• W4200490095 cites W2076214115 @default.
• W4200490095 cites W2094727696 @default.
• W4200490095 cites W2112669742 @default.
• W4200490095 cites W2116567300 @default.
• W4200490095 cites W2121756841 @default.
• W4200490095 cites W2140513528 @default.
• W4200490095 cites W2140548061 @default.
• W4200490095 cites W2147728116 @default.
• W4200490095 cites W2153941399 @default.
• W4200490095 cites W2157036549 @default.
• W4200490095 cites W2337220738 @default.
• W4200490095 cites W2407216154 @default.
• W4200490095 cites W2609605008 @default.
• W4200490095 cites W2754799758 @default.
• W4200490095 cites W2768267412 @default.
• W4200490095 cites W2783873885 @default.
• W4200490095 cites W2904387867 @default.
• W4200490095 cites W39103212 @default.
• W4200490095 doi "https://doi.org/10.18553/jmcp.2022.28.1.16" @default.
• W4200490095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34949121" @default.
• W4200490095 hasPublicationYear "2022" @default.
• W4200490095 type Work @default.
• W4200490095 citedByCount "0" @default.
• W4200490095 crossrefType "journal-article" @default.
• W4200490095 hasAuthorship W4200490095A5010339189 @default.
• W4200490095 hasAuthorship W4200490095A5018333483 @default.
• W4200490095 hasAuthorship W4200490095A5021745572 @default.
• W4200490095 hasAuthorship W4200490095A5030359301 @default.
• W4200490095 hasAuthorship W4200490095A5035903999 @default.
• W4200490095 hasAuthorship W4200490095A5038649200 @default.
• W4200490095 hasAuthorship W4200490095A5040321180 @default.
• W4200490095 hasAuthorship W4200490095A5042992461 @default.
• W4200490095 hasAuthorship W4200490095A5051667677 @default.
• W4200490095 hasAuthorship W4200490095A5054838830 @default.
• W4200490095 hasAuthorship W4200490095A5071453510 @default.
• W4200490095 hasAuthorship W4200490095A5086117406 @default.
• W4200490095 hasAuthorship W4200490095A5087248896 @default.
• W4200490095 hasAuthorship W4200490095A5090025434 @default.
• W4200490095 hasConcept C126322002 @default.
• W4200490095 hasConcept C134018914 @default.
• W4200490095 hasConcept C159641895 @default.
• W4200490095 hasConcept C167135981 @default.
• W4200490095 hasConcept C194828623 @default.
• W4200490095 hasConcept C197934379 @default.
• W4200490095 hasConcept C201903717 @default.
• W4200490095 hasConcept C2779159551 @default.
• W4200490095 hasConcept C2780243291 @default.
• W4200490095 hasConcept C2780306776 @default.
• W4200490095 hasConcept C44249647 @default.
• W4200490095 hasConcept C555293320 @default.
• W4200490095 hasConcept C71924100 @default.
• W4200490095 hasConcept C72563966 @default.
• W4200490095 hasConcept C82789193 @default.
• W4200490095 hasConceptScore W4200490095C126322002 @default.
• W4200490095 hasConceptScore W4200490095C134018914 @default.
• W4200490095 hasConceptScore W4200490095C159641895 @default.
• W4200490095 hasConceptScore W4200490095C167135981 @default.
• W4200490095 hasConceptScore W4200490095C194828623 @default.
• W4200490095 hasConceptScore W4200490095C197934379 @default.
• W4200490095 hasConceptScore W4200490095C201903717 @default.
• W4200490095 hasConceptScore W4200490095C2779159551 @default.
• W4200490095 hasConceptScore W4200490095C2780243291 @default.
• W4200490095 hasConceptScore W4200490095C2780306776 @default.
• W4200490095 hasConceptScore W4200490095C44249647 @default.
• W4200490095 hasConceptScore W4200490095C555293320 @default.
• W4200490095 hasConceptScore W4200490095C71924100 @default.
• W4200490095 hasConceptScore W4200490095C72563966 @default.
• W4200490095 hasConceptScore W4200490095C82789193 @default.

• next